Alzheimer's drug gets FDA panel's backing, setting the stage for broader use

[jmbar2]

1. Good news, with caveats...

Leqembi is the first drug that’s been convincingly shown to slow Alzheimer’s by targeting the underlying biology of the disease. The delay in progression amounts to about five months..

The drug was also associated with potentially serious side effects, including swelling of the brain and small bleeds in brain vessels.

Estimated cost $26,000 year, which could potentially drive up Medicare costs significantly due to the number of seniors with the disease. Hopefully the government can do something to drive down these costs.

Not a huge leap, but every step forward offers hope.